Cardiology Associations

This page includes news coverage of cardiology societies and associations. Follow these links for specific cardiology society news pages: American College of Cardiology (ACC), American Heart Association (AHA), American Society of Echocardiography (ASE), American Society Nuclear Cardiology (ASNC), European Society of Cardiology (ESC), Heart Rhythm Society (HRS), Society for Cardiovascular Angiography Interventions (SCAI), Society of Cardiovascular Computed Tomography (SCCT), Transcatheter Cardiovascular Therapeutics (TCT), and Vascular Interventional Advances (VIVA).

What every cardiologist should consider before signing a contract
Cathie Biga, MSN, MACC, explains why salary is just one thing a cardiologist should ask about before signing any contract.
SAPT after TAVR linked to key benefits over DAPT, new data confirm
All-cause mortality after six months was significantly lower for patients discharged on SAPT. That trend remained in place after 24 months.
American Heart Association takes on cardiac amyloidosis with new initiative
One of the project's biggest goals is helping clinicians identify patients in need of care earlier than ever.
Have clinicians been wrong about how they diagnose PAD?
The ankle-brachial index, a noninvasive diagnostic test for peripheral artery disease, may provide even more value than clinicians previously realized.
Conduction system pacing after TAVR linked to improved outcomes in new meta-analysis
Researchers explored data from nearly 800 patients, focusing on a wide variety of outcomes.

Deepak Bhatt discusses the MOMENTUM STUDY and the prevalence of hypercortisolism hypertension. #ACC #ACC26

New data highlight an unexpected link between hypercortisolism and resistant hypertension

Clinicians may need to broaden their diagnostic approach when treating and managing patients with resistant hypertension.

Edwards Evoque transcatheter tricuspid valve replacement TTVR

PVL after TTVR linked to much lower survival rate, fewer clinical benefits

TTVR has made a major impact on heart patients all over the world. Just like aortic and mitral valve replacement, however, paravalvular leak is a serious complication that can lead to much worse outcomes.

Video interview with Ronald Crystal, MD, chair, Department of Genetic Medicine at Weill Cornell Medicine, presented late-breaking findings on a first in-human, virus-delivered gene therapy trial to stop cardiomyopathy death in patients with Friedreich Ataxia (FA). #ACC #ACC26

New gene therapy may help protect the hearts of patients with Friedreich's ataxia

A majority of deaths from Friedreich's ataxia are associated with heart complications. A new treatment years in the making could provide some much-needed relief.

Prem Soman, MD, director of the Cardiac Amyloidosis Center and nuclear cardiology, and associate chief of cardiology at the University of Pittsburgh Medical Center Heart and Vascular Institute presented the late-breaking results from the long-term survival benefits and disease stabilization with the drug acoramidis in patients with transthyretin amyloid cardiomyopathy at ACC 2026.

Long-term cardiac amyloidosis survival benefits seen in extension acoramidis trial

Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy.

To unpack the large number of lat-breaking trials at the American College of Cardiology 2026 meeting, Cardiovascular Business spoke in the above video interview with Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, director of the Mount Sinai Fuster Heart Hospital, who highlighted several studies he felt had the most scientific impact. This included a mix of drug, device and strategy trials pointing to advances in cardiology. #ACC #ACC26

Deepak Bhatt discusses some of the most impactful trials at ACC 2026

Bhatt describes a mix of drug, device and strategy trials pointing to advances in cardiovascular science.

Kathryn Berlacher, MD, MS, FACC, chair of the 2026 American College of Cardiology (ACC) 2026 Scientific Sessions, and clinical director of cardiology and a women's heart and cardio-obstetrics specialist at the University of Pittsburgh Medical Center, explains the major trend of artificial intelligence (AI) in cardiology, the use of coronary CT angiography (CCTA) for the first time at a medical meeting to scan attendees, and the rise in hands on, guideline, business and advocacy sessions.

Impactful innovations reshape learning and technology at ACC.26

ACC.26 Chair Kathryn Berlacher, MD, MS, explained some of the big trends at this year's meeting, including AI, CCTA, hands-on training and guideline sessions.

Lower Medicare drug costs translated into more patients taking their medications, leading to better outcomes.

AI-powered EHR alerts make a world of difference for cardiologists, heart patients

AI can help care teams identify heart patients who would benefit from TAVR or another life-changing valve intervention.

Cardiology Associations

What every cardiologist should consider before signing a contract

SAPT after TAVR linked to key benefits over DAPT, new data confirm

American Heart Association takes on cardiac amyloidosis with new initiative

Have clinicians been wrong about how they diagnose PAD?

Conduction system pacing after TAVR linked to improved outcomes in new meta-analysis